Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05552222
Registration number
NCT05552222
Ethics application status
Date submitted
21/09/2022
Date registered
23/09/2022
Titles & IDs
Public title
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Query!
Scientific title
A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy
Query!
Secondary ID [1]
0
0
64007957MMY3005
Query!
Secondary ID [2]
0
0
CR109237
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
MajesTEC-7
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Other cancer types
Query!
Intervention/exposure
Study type
Interventional(has expanded access)
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Teclistamab
Treatment: Drugs - Daratumumab
Treatment: Drugs - Lenalidomide
Treatment: Drugs - Dexamethasone
Treatment: Drugs - Talquetamab
Experimental: Teclistamab, Daratumumab SC, and Lenalidomide (Tec-DR) - Participants will receive teclistamab as subcutaneous (SC) injection in combination with daratumumab and lenalidomide.
Experimental: Talquetamab, Daratumumab SC, and Lenalidomide (Tal-DR) - Participants will receive talquetamab as SC injection in combination with daratumumab and lenalidomide.
Active comparator: Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) - Participants will receive daratumumab as SC injection with lenalidomide and dexamethasone.
Treatment: Drugs: Teclistamab
Teclistamab will be administered as SC injection.
Treatment: Drugs: Daratumumab
Daratumumab will be administered as SC injection.
Treatment: Drugs: Lenalidomide
Lenalidomide will be administered orally.
Treatment: Drugs: Dexamethasone
Dexamethasone will be administered either orally or intravenously (IV).
Treatment: Drugs: Talquetamab
Talquetamab will be administered as SC injection.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression Free Survival (PFS)
Query!
Assessment method [1]
0
0
PFS is defined as the duration from the date of randomization to either progressive disease or death, whichever comes first. Disease progression will be determined according to the International Myeloma Working Group (IMWG) response criteria.
Query!
Timepoint [1]
0
0
From randomization to the date of disease progression or death (Up to 09 years)
Query!
Primary outcome [2]
0
0
12-Month Minimal Residual Disease (MRD)-Negative Complete Response (CR)
Query!
Assessment method [2]
0
0
12-month MRD-negative CR is defined as participants who achieve MRD-negative status at 12 months, as determined by next-generation sequencing (NGS) with sensitivity of 10\^-5, prior to progressive disease or subsequent anti-myeloma therapy and who also achieve CR or better, according to IMWG criteria.
Query!
Timepoint [2]
0
0
At Month 12
Query!
Secondary outcome [1]
0
0
Very Good Partial Response (VGPR) or Better
Query!
Assessment method [1]
0
0
VGPR or better is defined as the percentage of participants achieving VGPR and CR (including stringent complete response \[sCR\]) prior to subsequent antimyeloma therapy in accordance with the IMWG criteria during or after the study treatment.
Query!
Timepoint [1]
0
0
From randomization up to 09 years
Query!
Secondary outcome [2]
0
0
Complete Response (CR) or Better
Query!
Assessment method [2]
0
0
CR or better is defined as the percentage of participants achieving CR or sCR prior to subsequent antimyeloma therapy in accordance with the IMWG criteria during or after the study treatment.
Query!
Timepoint [2]
0
0
From randomization up to 09 years
Query!
Secondary outcome [3]
0
0
Sustained Minimal Residual disease (MRD)-negative Complete Response (CR)
Query!
Assessment method [3]
0
0
Sustained MRD-negative CR is defined as participants with CR or better who sustain MRD-negative status, as determined by NGS with sensitivity of 10\^-5, for at least 12 months without any examination showing MRD positive status or progressive disease in between.
Query!
Timepoint [3]
0
0
From randomization up to 09 years
Query!
Secondary outcome [4]
0
0
MRD-negative CR
Query!
Assessment method [4]
0
0
MRD-negative CR is defined as the percentage of participants who achieve MRD-negative status, as determined by NGS with sensitivity of 10\^-5, at any time after randomization and prior to progressive disease or subsequent antimyeloma therapy and who achieve CR or better.
Query!
Timepoint [4]
0
0
From randomization up to 09 years
Query!
Secondary outcome [5]
0
0
Progression Free Survival on Next-line Therapy (PFS2)
Query!
Assessment method [5]
0
0
PFS2 is defined as the time interval between the date of randomization and date of event, which is defined as progressive disease as assessed by investigator that starts after the next line of subsequent therapy, or death from any cause, whichever occurs first.
Query!
Timepoint [5]
0
0
From randomization up to 09 years
Query!
Secondary outcome [6]
0
0
Overall Survival (OS)
Query!
Assessment method [6]
0
0
OS is defined as the time from the date of randomization to the date of death due to any cause.
Query!
Timepoint [6]
0
0
From randomization to the date of death (up to 09 years)
Query!
Secondary outcome [7]
0
0
Number of Participants with Adverse Events (AEs) by Severity
Query!
Assessment method [7]
0
0
An adverse event is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the treatment. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening, and Grade 5: death related to adverse event.
Query!
Timepoint [7]
0
0
From randomization up to 09 years
Query!
Secondary outcome [8]
0
0
Number of Participants with Abnormalities in Laboratory Parameters
Query!
Assessment method [8]
0
0
Number of participants with abnormalities in laboratory parameters (serum chemistry and hematology) will be reported.
Query!
Timepoint [8]
0
0
From randomization up to 09 years
Query!
Secondary outcome [9]
0
0
Number of Participants with Abnormalities in Vital Signs
Query!
Assessment method [9]
0
0
Number of participants with abnormalities in vital signs (temperature, pulse/heart rate, respiratory rate, blood pressure) will be reported.
Query!
Timepoint [9]
0
0
From randomization up to 09 years
Query!
Secondary outcome [10]
0
0
Number of Participants with Abnormalities in Physical Examination
Query!
Assessment method [10]
0
0
Number of participants with abnormalities in physical examination will be reported.
Query!
Timepoint [10]
0
0
From randomization up to 09 years
Query!
Secondary outcome [11]
0
0
Number of Participants with Abnormalities in Electrocardiogram (ECG)
Query!
Assessment method [11]
0
0
Number of participants with abnormalities in ECG will be reported.
Query!
Timepoint [11]
0
0
From randomization up to 09 years
Query!
Secondary outcome [12]
0
0
Serum Concentrations of Teclistamab and Talquetamab
Query!
Assessment method [12]
0
0
Serum samples will be analyzed to determine concentrations of teclistamab and talquetamab using validated, specific, and sensitive methods.
Query!
Timepoint [12]
0
0
From randomization up to 09 years
Query!
Secondary outcome [13]
0
0
Number of Participants with Anti-drug Antibodies (ADAs) to Teclistamab and Talquetamab
Query!
Assessment method [13]
0
0
Number of participants with ADAs to teclistamab and talquetamab will be reported.
Query!
Timepoint [13]
0
0
From randomization up to 09 years
Query!
Secondary outcome [14]
0
0
Change from Baseline in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30)
Query!
Assessment method [14]
0
0
The EORTC-QLQ-C30 Version 3 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 5 single symptom items (dyspnea, insomnia, appetite loss, constipation, and diarrhea) and a single impact item (financial difficulties). The recall period is 7 days ("past week"), and responses are reported using a verbal and numeric rating scales. The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status represents high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.
Query!
Timepoint [14]
0
0
From baseline up to 9 years
Query!
Secondary outcome [15]
0
0
Change from Baseline in Treatment-related Symptoms as Assessed by Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Query!
Assessment method [15]
0
0
The National Cancer Institute's (NCI's) PRO-CTCAE is an item library of common AEs experienced by people with cancer that are appropriate for self-reporting of treatment tolerability. Each symptom selected for inclusion can be rated by up to 3 attributes characterizing the presence/frequency, severity, and/or interference of the AEs. It ranges from 0 to 4 with higher scores indicating higher frequency or greater severity/impact.
Query!
Timepoint [15]
0
0
Baseline through Cycle 6 (each cycle of 28 days) (up to 196 days)
Query!
Secondary outcome [16]
0
0
Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)
Query!
Assessment method [16]
0
0
The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).
Query!
Timepoint [16]
0
0
From baseline up to 9 years
Query!
Secondary outcome [17]
0
0
Time to Sustained Worsening in Symptoms, Functioning, and HRQoL
Query!
Assessment method [17]
0
0
Time to sustained worsening in symptoms, functioning and HRQoL is defined as the interval from the date of randomization to the start date of meaningful change.
Query!
Timepoint [17]
0
0
From randomization up to 09 years
Query!
Eligibility
Key inclusion criteria
* Have a diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria
* Be newly diagnosed and not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT) due to: ineligible due to advanced age OR; ineligible due to the presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT OR; deferral of high-dose chemotherapy with ASCT as initial treatment
* Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
* A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment
* A participant must agree not to plan to father a child while enrolled in this study or within 100 days after the last dose of study treatment
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Received any prior therapy for multiple myeloma or smoldering myeloma other than a short course of corticosteroids (not to exceed total of 160 milligrams [mg] dexamethasone or equivalent). In addition, received a cumulative dose of systemic corticosteroids equivalent to greater than or equals to (>=) 20 mg of dexamethasone within 14 days before randomization
* Had plasmapheresis within 28 days of randomization
* Had a stroke, transient ischemic attack, or seizure within 6 months prior to randomization
* Known allergies, hypersensitivity, or intolerance to teclistamab or talquetamab excipients
* Known contraindications to the use of daratumumab or lenalidomide per local prescribing information
* Myeloma Frailty Index of >=2 with the exception of participants who have a score of 2 based on age alone
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
25/10/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
28/10/2033
Query!
Actual
Query!
Sample size
Target
1590
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Royal Prince Alfred Hospital - Camperdown
Query!
Recruitment hospital [2]
0
0
Barwon Health - University Hospital Geelong - Geelong
Query!
Recruitment hospital [3]
0
0
Liverpool Hospital - Liverpool
Query!
Recruitment hospital [4]
0
0
Sir Charles Gairdner Hospital - Nedlands
Query!
Recruitment hospital [5]
0
0
Calvary Mater Newcastle Hospital - New South Wales
Query!
Recruitment hospital [6]
0
0
Wollongong Hospital - Wollongong
Query!
Recruitment hospital [7]
0
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
3220 - Geelong
Query!
Recruitment postcode(s) [3]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [4]
0
0
6009 - Nedlands
Query!
Recruitment postcode(s) [5]
0
0
2298 - New South Wales
Query!
Recruitment postcode(s) [6]
0
0
2500 - Wollongong
Query!
Recruitment postcode(s) [7]
0
0
4102 - Woolloongabba
Query!
Recruitment outside Australia
Country [1]
0
0
Austria
Query!
State/province [1]
0
0
Linz
Query!
Country [2]
0
0
Austria
Query!
State/province [2]
0
0
Salzburg
Query!
Country [3]
0
0
Belgium
Query!
State/province [3]
0
0
Anderlecht
Query!
Country [4]
0
0
Belgium
Query!
State/province [4]
0
0
Gent
Query!
Country [5]
0
0
Belgium
Query!
State/province [5]
0
0
Haine Saint Paul La Louviere
Query!
Country [6]
0
0
Belgium
Query!
State/province [6]
0
0
Kortrijk
Query!
Country [7]
0
0
Belgium
Query!
State/province [7]
0
0
Leuven
Query!
Country [8]
0
0
Belgium
Query!
State/province [8]
0
0
Wilrijk
Query!
Country [9]
0
0
Brazil
Query!
State/province [9]
0
0
Barretos
Query!
Country [10]
0
0
Brazil
Query!
State/province [10]
0
0
Belo Horizonte
Query!
Country [11]
0
0
Brazil
Query!
State/province [11]
0
0
Curitiba
Query!
Country [12]
0
0
Brazil
Query!
State/province [12]
0
0
Fortaleza
Query!
Country [13]
0
0
Brazil
Query!
State/province [13]
0
0
Natal
Query!
Country [14]
0
0
Brazil
Query!
State/province [14]
0
0
Niteroi
Query!
Country [15]
0
0
Brazil
Query!
State/province [15]
0
0
Porto Alegre
Query!
Country [16]
0
0
Brazil
Query!
State/province [16]
0
0
Ribeirao Preto
Query!
Country [17]
0
0
Brazil
Query!
State/province [17]
0
0
Salvador
Query!
Country [18]
0
0
Brazil
Query!
State/province [18]
0
0
Sao Paulo
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Alberta
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Quebec
Query!
Country [21]
0
0
China
Query!
State/province [21]
0
0
Beijing
Query!
Country [22]
0
0
China
Query!
State/province [22]
0
0
Chang Zhou
Query!
Country [23]
0
0
China
Query!
State/province [23]
0
0
Changchun
Query!
Country [24]
0
0
China
Query!
State/province [24]
0
0
Changsha
Query!
Country [25]
0
0
China
Query!
State/province [25]
0
0
Chaoyang District
Query!
Country [26]
0
0
China
Query!
State/province [26]
0
0
Fu Zhou
Query!
Country [27]
0
0
China
Query!
State/province [27]
0
0
Guangzhou
Query!
Country [28]
0
0
China
Query!
State/province [28]
0
0
Harbin
Query!
Country [29]
0
0
China
Query!
State/province [29]
0
0
Jinan
Query!
Country [30]
0
0
China
Query!
State/province [30]
0
0
Nan Jing
Query!
Country [31]
0
0
China
Query!
State/province [31]
0
0
Nan Ning Shi
Query!
Country [32]
0
0
China
Query!
State/province [32]
0
0
Nanchang
Query!
Country [33]
0
0
China
Query!
State/province [33]
0
0
Shanghai
Query!
Country [34]
0
0
China
Query!
State/province [34]
0
0
Shenyang
Query!
Country [35]
0
0
China
Query!
State/province [35]
0
0
Tian Jin
Query!
Country [36]
0
0
China
Query!
State/province [36]
0
0
Tianjin
Query!
Country [37]
0
0
China
Query!
State/province [37]
0
0
Wenzhou
Query!
Country [38]
0
0
China
Query!
State/province [38]
0
0
WuHan
Query!
Country [39]
0
0
Czechia
Query!
State/province [39]
0
0
Brno - Bohunice
Query!
Country [40]
0
0
Czechia
Query!
State/province [40]
0
0
Hradec Kralove
Query!
Country [41]
0
0
Czechia
Query!
State/province [41]
0
0
Olomouc
Query!
Country [42]
0
0
Czechia
Query!
State/province [42]
0
0
Ostrava
Query!
Country [43]
0
0
Czechia
Query!
State/province [43]
0
0
Plzen
Query!
Country [44]
0
0
Czechia
Query!
State/province [44]
0
0
Praha
Query!
Country [45]
0
0
Denmark
Query!
State/province [45]
0
0
Vejle
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Creteil
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Lille
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Nantes
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
PARIS cedex 12
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Pessac cedex
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Pierre-Benite
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Poitiers
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Rennes
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Strasbourg
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Toulouse
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Berlin
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Halle (Saale)
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Hamburg
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Nuernberg
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Tübingen
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Wurzburg
Query!
Country [62]
0
0
Greece
Query!
State/province [62]
0
0
Athens Attica
Query!
Country [63]
0
0
Greece
Query!
State/province [63]
0
0
Thessalonikis
Query!
Country [64]
0
0
Greece
Query!
State/province [64]
0
0
Thessaloniki
Query!
Country [65]
0
0
Israel
Query!
State/province [65]
0
0
Haifa
Query!
Country [66]
0
0
Israel
Query!
State/province [66]
0
0
Jerusalem
Query!
Country [67]
0
0
Israel
Query!
State/province [67]
0
0
Petah Tikva
Query!
Country [68]
0
0
Israel
Query!
State/province [68]
0
0
Ramat Gan
Query!
Country [69]
0
0
Israel
Query!
State/province [69]
0
0
Tel Aviv Yafo
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
Bologna
Query!
Country [71]
0
0
Italy
Query!
State/province [71]
0
0
Firenze
Query!
Country [72]
0
0
Italy
Query!
State/province [72]
0
0
Milan
Query!
Country [73]
0
0
Italy
Query!
State/province [73]
0
0
Pavia
Query!
Country [74]
0
0
Italy
Query!
State/province [74]
0
0
Roma
Query!
Country [75]
0
0
Italy
Query!
State/province [75]
0
0
Rozzano
Query!
Country [76]
0
0
Italy
Query!
State/province [76]
0
0
Torino
Query!
Country [77]
0
0
Japan
Query!
State/province [77]
0
0
Bunkyo-Ku
Query!
Country [78]
0
0
Japan
Query!
State/province [78]
0
0
Chiba
Query!
Country [79]
0
0
Japan
Query!
State/province [79]
0
0
Higashiibaraki-gun
Query!
Country [80]
0
0
Japan
Query!
State/province [80]
0
0
Hirakata
Query!
Country [81]
0
0
Japan
Query!
State/province [81]
0
0
Hyôgo
Query!
Country [82]
0
0
Japan
Query!
State/province [82]
0
0
Iruma-gun
Query!
Country [83]
0
0
Japan
Query!
State/province [83]
0
0
Kanagawa
Query!
Country [84]
0
0
Japan
Query!
State/province [84]
0
0
Kanazawa
Query!
Country [85]
0
0
Japan
Query!
State/province [85]
0
0
Kumamoto-shi
Query!
Country [86]
0
0
Japan
Query!
State/province [86]
0
0
Matsuyama-City
Query!
Country [87]
0
0
Japan
Query!
State/province [87]
0
0
Nagasaki
Query!
Country [88]
0
0
Japan
Query!
State/province [88]
0
0
Okayama
Query!
Country [89]
0
0
Japan
Query!
State/province [89]
0
0
Osaka
Query!
Country [90]
0
0
Japan
Query!
State/province [90]
0
0
Shibukawa
Query!
Country [91]
0
0
Japan
Query!
State/province [91]
0
0
Yamagata
Query!
Country [92]
0
0
Japan
Query!
State/province [92]
0
0
Yamanashi
Query!
Country [93]
0
0
Korea, Republic of
Query!
State/province [93]
0
0
Busan
Query!
Country [94]
0
0
Korea, Republic of
Query!
State/province [94]
0
0
Goyang si
Query!
Country [95]
0
0
Korea, Republic of
Query!
State/province [95]
0
0
Hwasun
Query!
Country [96]
0
0
Korea, Republic of
Query!
State/province [96]
0
0
Incheon
Query!
Country [97]
0
0
Korea, Republic of
Query!
State/province [97]
0
0
Seoul
Query!
Country [98]
0
0
Netherlands
Query!
State/province [98]
0
0
Amsterdam
Query!
Country [99]
0
0
Netherlands
Query!
State/province [99]
0
0
Apeldoorn
Query!
Country [100]
0
0
Netherlands
Query!
State/province [100]
0
0
Delft
Query!
Country [101]
0
0
Netherlands
Query!
State/province [101]
0
0
Nieuwegein
Query!
Country [102]
0
0
Netherlands
Query!
State/province [102]
0
0
Sittard-Geleen
Query!
Country [103]
0
0
Norway
Query!
State/province [103]
0
0
Oslo
Query!
Country [104]
0
0
Norway
Query!
State/province [104]
0
0
Trondheim
Query!
Country [105]
0
0
Poland
Query!
State/province [105]
0
0
Brzozow
Query!
Country [106]
0
0
Poland
Query!
State/province [106]
0
0
Katowice
Query!
Country [107]
0
0
Poland
Query!
State/province [107]
0
0
Kielce
Query!
Country [108]
0
0
Portugal
Query!
State/province [108]
0
0
Braga
Query!
Country [109]
0
0
Portugal
Query!
State/province [109]
0
0
Lisbon
Query!
Country [110]
0
0
Portugal
Query!
State/province [110]
0
0
Porto
Query!
Country [111]
0
0
Spain
Query!
State/province [111]
0
0
Badalona
Query!
Country [112]
0
0
Spain
Query!
State/province [112]
0
0
Barcelona
Query!
Country [113]
0
0
Spain
Query!
State/province [113]
0
0
Granada
Query!
Country [114]
0
0
Spain
Query!
State/province [114]
0
0
Jerez de la Frontera
Query!
Country [115]
0
0
Spain
Query!
State/province [115]
0
0
Madrid
Query!
Country [116]
0
0
Spain
Query!
State/province [116]
0
0
Palma de Mallorca
Query!
Country [117]
0
0
Spain
Query!
State/province [117]
0
0
Pozuelo de Alarcon
Query!
Country [118]
0
0
Spain
Query!
State/province [118]
0
0
Salamanca
Query!
Country [119]
0
0
Spain
Query!
State/province [119]
0
0
Terrassa
Query!
Country [120]
0
0
Spain
Query!
State/province [120]
0
0
Valencia
Query!
Country [121]
0
0
Sweden
Query!
State/province [121]
0
0
Falun
Query!
Country [122]
0
0
Sweden
Query!
State/province [122]
0
0
Lund
Query!
Country [123]
0
0
Sweden
Query!
State/province [123]
0
0
Stockholm
Query!
Country [124]
0
0
Sweden
Query!
State/province [124]
0
0
Örebro
Query!
Country [125]
0
0
Switzerland
Query!
State/province [125]
0
0
Bern
Query!
Country [126]
0
0
Switzerland
Query!
State/province [126]
0
0
St. Gallen
Query!
Country [127]
0
0
Turkey
Query!
State/province [127]
0
0
Ankara
Query!
Country [128]
0
0
Turkey
Query!
State/province [128]
0
0
Denizli
Query!
Country [129]
0
0
Turkey
Query!
State/province [129]
0
0
Istanbul
Query!
Country [130]
0
0
Turkey
Query!
State/province [130]
0
0
Izmir
Query!
Country [131]
0
0
Turkey
Query!
State/province [131]
0
0
Samsun
Query!
Country [132]
0
0
United Kingdom
Query!
State/province [132]
0
0
Blackpool
Query!
Country [133]
0
0
United Kingdom
Query!
State/province [133]
0
0
Bristol
Query!
Country [134]
0
0
United Kingdom
Query!
State/province [134]
0
0
Canterbury
Query!
Country [135]
0
0
United Kingdom
Query!
State/province [135]
0
0
Edinburgh
Query!
Country [136]
0
0
United Kingdom
Query!
State/province [136]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Janssen Research & Development, LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).
Query!
Trial website
https://clinicaltrials.gov/study/NCT05552222
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Janssen Research & Development, LLC Clinical Trial
Query!
Address
0
0
Janssen Research & Development, LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Study Contact
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
844-434-4210
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Query!
When will data be available (start and end dates)?
Query!
Available to whom?
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://www.janssen.com/clinical-trials/transparency
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT05552222